COR vs IDXX vs ZSTK Stock Comparison

Cencora, Idexx Laboratories and ZeroStack Prices as of Oct 29, 2026 Peers: Industry group
COR Cencora, Inc.
$330.64 +7.5% 1M -0.8% 1Y
Market cap
$63.87B
P/E
24.3x
Revenue (TTM)
$332.77B
Div. yield
0.01%
Drug Distribution Healthcare
5 wins
ZSTK ZeroStack Corp.
$2.93 -39.5% 1M -71.7% 1Y
Market cap
$29.09M
P/E
–
Revenue (TTM)
$40.03M
Div. yield
–
Drug Distribution Healthcare
2 wins

Head to Head

11 decided of 12

Cencora leads on 5 of the 12 questions below (Cencora 5, Idexx Laboratories 4, ZeroStack 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCORIDXXZSTKLeader
Larger companyMarket capitalisation $63.87B $43.52B $29.09M COR
Cheaper on earningsLower P/E, profitable companies only 24.3x 38.2x -0.2x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.4x 36.9x — COR
Faster revenue growthRevenue growth, trailing twelve months +5.1% +12.8% +27.3% ZSTK
More profitableNet margin, trailing twelve months 0.8% 25.0% -444.3% IDXX
Better return on capitalReturn on invested capital 14.4% 45.6% -852.2% IDXX
Less leveragedLower net debt / EBITDA 2.2x 0.5x 0.0x ZSTK
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -0.8% -8.2% -71.7% COR
Better 5-year returnAnnualised price return, 5 years +22.1%/yr -2.9%/yr -75.6%/yr COR
Less volatileAnnualised volatility, 1 year 32.8% 32.1% 169.3% IDXX
Higher overall scoreMean of the five percentile scores vs peers 54/100 77/100 26/100 IDXX

Percentile Scorecard

CORIDXXZSTK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCORIDXXZSTK
Valuation 63 #10 of 25 75 #155 of 624 17 #21 of 25
Growth 74 #7 of 24 76 #148 of 601 44 #14 of 24
Profitability 61 #10 of 24 97 #17 of 541 9 #22 of 24
Financial Health 24 #20 of 26 46 #350 of 647 60 #11 of 26
Shareholder Returns 47 #9 of 16 93 #26 of 359 0 #16 of 16
Overall 54 77 26
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • IDXX ranked among 671 companies in Pharmaceuticals and Biotechnology
  • ZSTK ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCORIDXXZSTKSPY
1 month +7.5%+8.0%-39.5% +0.7%
3 months +5.9%+3.1%+90.3% +3.7%
6 months +7.3%+2.7%-50.8% +7.1%
Year to date -2.1%-14.9%-53.2% +12.8%
1 year -0.8%-8.2%-71.7% +11.9%
3 years +78.3%+45.3%-89.8% +85.2%
3 years, per year +21.3%+13.3%-53.3% +22.8%
5 years +171.0%-13.5%-99.9% +67.6%
5 years, per year +22.1%-2.9%-75.6% +10.9%
10 years +378.2%+448.3%— +262.0%
10 years, per year +16.9%+18.6%— +13.7%

Risk

MeasureCORIDXXZSTKSPY
Volatility, 1Y 32.8%32.1%169.3% 12.7%
Downside volatility, 1Y 39.7%31.3%132.1% 12.6%
Beta vs S&P 500, 1Y -0.160.791.68 1.00
Return / volatility, 1Y -0.02-0.26-0.42 0.94
Max drawdown, 5Y -32.6%-51.3%-100.0% -25.4%
From 52-week high -11.8%-24.9%-75.2% -1.2%
52-week high $374.75$766.68$11.80 $779.14
52-week low $252.74$504.70$1.37 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCORIDXXZSTK
P/E now vs peer median 24.3xmedian 24.3x 39.9xmedian 17.8x -0.2xmedian 24.3x
P/S now vs peer median 0.2xmedian 0.3x 10.0xmedian 9.1x 0.7xmedian 0.3x
EV/EBITDA now vs peer median 17.5xmedian 12.9x 28.6xmedian 15.0x -0.1xmedian 12.9x
P/FCF now vs peer median 15.5xmedian 16.4x 36.2xmedian 21.7x -5.2xmedian 16.4x
P/B now vs peer median 19.5xmedian 2.5x 28.2xmedian 2.2x 2.1xmedian 2.5x
PEG now vs peer median 1.36median 1.36 2.64median 0.35 0.00median 1.36

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCORIDXXZSTK
Revenue $332.77B $4.55B $40.03M
Gross profit $13.22B $2.84B $5.26M
Operating income $3.04B $1.46B -$239.39M
Net income $2.65B $1.14B -$177.88M
Free cash flow $4.06B $1.25B -$5.64M
R&D – $261.47M –
EPS (diluted) $13.53 $14.37 $-17.86
Cash & equivalents $2.82B $196.93M $2.64M
Total debt $11.72B $968.86M $2.41M
Shares (diluted) 193.94M 79.31M 9.96M
Enterprise value $52.77B $42.73B $5.77M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCORIDXXZSTK
P/E 24.3x 39.9x -0.2x
P/FCF 15.5x 36.2x -5.2x
P/Operating cash flow 13.1x 33.1x -5.2x
P/S 0.2x 10.0x 0.7x
P/B 19.5x 28.2x 2.1x
P/Tangible book -23.4x 30.0x 2.1x
EV/EBITDA 17.5x 28.6x -0.1x
EV/EBIT 23.7x 31.7x -0.1x
EV/Revenue 0.2x 10.1x 0.7x
EV/FCF 17.7x 36.8x -5.1x
EV/Operating cash flow 14.9x 33.7x -5.2x
PEG (3Y EPS CAGR) 1.36 2.64 0.00

Growth

14 metrics
MetricCORIDXXZSTK
Revenue growth (1Y) 5.1% 12.8% 27.3%
Revenue CAGR (3Y) 9.4% 9.0% -13.1%
Gross profit growth (1Y) 20.0% 14.4% 171.8%
Gross profit CAGR (3Y) 15.0% 10.5% -32.4%
Operating income growth (1Y) 11.1% 16.2% -2,574%
Operating income CAGR (3Y) 9.5% 11.7% -57.0%
Net income growth (1Y) 38.9% 15.6% -1,263%
Net income CAGR (3Y) 16.2% 12.9% -37.3%
EPS growth (1Y) 39.3% 18.1% 24.9%
EPS CAGR (3Y) 17.9% 15.1% 64.4%
Operating cash flow growth (1Y) 176.7% 51.4% 37.6%
Operating cash flow CAGR (3Y) 14.1% 22.5% 23.9%
Free cash flow growth (1Y) 255.7% 59.9% 37.9%
Free cash flow CAGR (3Y) 13.3% 28.4% 25.2%

Profitability

14 metrics
MetricCORIDXXZSTK
Gross margin 4.0% 62.4% 13.1%
EBITDA margin 1.2% 35.4% -597.5%
Operating margin 0.9% 32.0% -598.0%
Pretax margin 1.1% 31.3% -436.1%
Net margin 0.8% 25.0% -444.3%
FCF margin 1.2% 27.5% -14.1%
Operating cash flow margin 1.4% 30.1% -14.0%
Return on equity 77.4% 71.9% -702.9%
Return on assets 3.2% 33.4% -505.5%
Return on invested capital 14.4% 45.6% -852.2%
Return on capital employed 12.9% 68.6% -994.1%
Asset turnover 4.0x 1.3x 1.1x
Cash conversion (OCF / net income) 1.8x 1.2x 0.0x
Stock comp / revenue 0.0% 1.4% 13.1%

Financial Health

11 metrics
MetricCORIDXXZSTK
Debt / assets 14.0% 28.1% 9.6%
Debt / equity 3.6x 0.6x 0.2x
Net debt / EBITDA 2.2x 0.5x 0.0x
Debt / FCF 2.9x 0.8x -0.4x
Liabilities / assets 96.1% 53.2% 45.1%
Equity / assets 3.9% 46.8% 54.9%
Interest coverage – 38.6x –
Current ratio 0.9x 1.2x 0.9x
Quick ratio 0.5x 0.7x 0.7x
Cash ratio 0.0x 0.2x 0.2x
Altman Z-score 4.66 20.55 -47.11

Shareholder Returns

7 metrics
MetricCORIDXXZSTK
Dividend yield 0.7% – –
Net buyback yield 1.6% 2.3% -51.5%
Shareholder yield 2.3% 2.3% -51.5%
Payout ratio (earnings) 17.7% – –
Payout ratio (FCF) 11.5% – –
Dividend growth (1Y) 8.7% – –
Dividend CAGR (3Y) 5.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCORIDXXZSTK
Forward P/E 19.4xFY2026 36.9xFY2026 –
EPS, next fiscal year $17.08FY2026 $15.63FY2026 $-4.29FY2026
EPS growth, next FY +6.7%FY2026 +19.5%FY2026 –
EPS growth, the year after +11.8% +12.9% –
Revenue, next fiscal year $328.56BFY2026 $5.00BFY2026 $31.29MFY2026
Revenue growth, next FY +2.2%FY2026 +16.3%FY2026 -12.3%FY2026
Revenue growth, the year after -0.3% +0.6% -10.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCORIDXXZSTK
Held by institutions 94.7% 93.6% –
Institutions holding 1,344 1,290 –
Change in shares held, QoQ +15.7% +4.1% –
Institutions buying 542 588 –
Institutions selling 611 496 –
Buyers to sellers 0.89 1.19 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CORIDXXZSTK
COR 1.00 0.12 0.01
IDXX 0.12 1.00 0.10
ZSTK 0.01 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, COR, IDXX and ZSTK?

Cencora (COR) is the largest by market capitalisation: Cencora (COR) $63.87B, Idexx Laboratories (IDXX) $43.52B, ZeroStack (ZSTK) $29.09M.

Which stock is cheaper, COR, IDXX and ZSTK?

Cencora (COR) trades on the lowest price-to-earnings ratio (Cencora (COR) 24.3x, Idexx Laboratories (IDXX) 38.2x, ZeroStack (ZSTK) -0.2x). On next year's consensus earnings, Cencora (COR) is cheapest (Cencora (COR) 19.4x, Idexx Laboratories (IDXX) 36.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

ZeroStack (ZSTK) grew revenue fastest over the trailing twelve months: Cencora (COR) +5.1%, Idexx Laboratories (IDXX) +12.8%, ZeroStack (ZSTK) +27.3%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Cencora (COR) 0.8%, Idexx Laboratories (IDXX) 25.0%, ZeroStack (ZSTK) -444.3%). On return on invested capital, Idexx Laboratories (IDXX) leads (Cencora (COR) 14.4%, Idexx Laboratories (IDXX) 45.6%, ZeroStack (ZSTK) -852.2%).

Which stock has performed better?

Over the past year Cencora (COR) returned the most: Cencora (COR) -0.8%, Idexx Laboratories (IDXX) -8.2%, ZeroStack (ZSTK) -71.7%. Over five years, Cencora (COR) compounded fastest (Cencora (COR) +22.1%/yr, Idexx Laboratories (IDXX) -2.9%/yr, ZeroStack (ZSTK) -75.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Cencora (COR) 0.01%, Idexx Laboratories (IDXX) 0.00%, ZeroStack (ZSTK) 0.00%. Idexx Laboratories (IDXX) and ZeroStack (ZSTK) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Cencora (COR) 32.8%, Idexx Laboratories (IDXX) 32.1%, ZeroStack (ZSTK) 169.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, COR, IDXX and ZSTK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cencora (COR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.